GI Esophageal / Gastric

**Localized**

- IRB #12071
  - A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients with Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI

**HER 2+**

- 1st Line
  - No Trials Currently Available
- 2nd Line
  - IRB #15349
    - Keynote-181
      - A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

**HER 2-**

- 1st Line
  - IRB# 15706
    - EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
- 2nd Line
  - IRB #15349
    - Keynote-181
      - A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

[Key]

- Open for Enrollment
- In Development
- Enrollment on Hold

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)